ActHIB set to finally reach the Japanese market
This article was originally published in Scrip
The much-delayed Japanese launch of Sanofi Pasteur-Daiichi Sankyo Vaccines' paediatric meningitis vaccine ActHIB will take place on December 19th. The Haemophilus influenzae type b prophylactic vaccine was approved in the country back in January 2007, but batch production to Japanese standards took longer than expected. The product will be distributed by Daiichi Sankyo, and is not currently eligible for reimbursement under Japan's national insurance scheme.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.